List of Aloxi drug patents
Aloxi is owned by Helsinn Hlthcare.
Aloxi contains Palonosetron Hydrochloride.
Aloxi has a total of 26 drug patents out of which 0 drug patents have expired.
Aloxi was authorised for market use on 25 July, 2003.
Aloxi is available in injectable;intravenous dosage forms.
Aloxi can be used as prevention of chemotherapy-induced nausea and vomiting.
The generics of Aloxi are possible to be released after 30 July, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9066980 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US8729094 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US9457020 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US8518981 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US9439854 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US7947725 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US8598218 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US9457021 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US9125905 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US7960424 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US9173942 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US7947724 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
| US8598219 | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jan, 2024
(10 months from now) | |
|
US7947724
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US7947725
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US7960424
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US8518981
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US8598218
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US9173942
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US9439854
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US9457020
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US8729094
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US8598219
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US9125905
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US9457021
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
|
US9066980
(Pediatric) | HELSINN HLTHCARE | Liquid pharmaceutical formulations of palonosetron |
Jul, 2024
(1 year, 4 months from now) | |
Drugs and Companies using PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 25 July, 2003
Treatment: Prevention of chemotherapy-induced nausea and vomiting
Dosage: INJECTABLE;INTRAVENOUS
ALOXI family patents
20
United States
5
Canada
3
European Union
2
China
2
Japan
1
Portugal
1
Germany
1
Malaysia
1
Uruguay
1
Panama
1
Spain
1
Jordan
1
Brazil
1
Croatia
1
Costa Rica
1
New Zealand
1
AP
1
Norway
1
Argentina
1
Austria
1
Mexico
1
Morocco
1
Peru
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
Tunisia
1
South Africa
1
Cyprus
1
Slovenia
1
Yugoslavia
1
Iceland
1
Israel
1
Ukraine
1
Georgia
1
Poland
1
Australia
1
Ecuador
1
Denmark
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic